Effects of intestinal flora on pharmacokinetics and pharmacodynamics of drugs

References

• Adak A, Khan MR. 2019. An insight into gut microbiota and its functionalities. Cell Mol Life Sci. 76(3):473–493.
   PubMed Web of Science ®Google Scholar
• Adamiak U, Kaldonska M, Klodowska-Duda G, Wyska E, Safranow K, Bialecka M, Gawronska-Szklarz B. 2010. Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease. Clin Neuropharmacol. 33(3):135–141.
   PubMed Web of Science ®Google Scholar
• Aoki R, Kamikado K, Suda W, Takii H, Mikami Y, Suganuma N, Hattori M, Koga Y. 2017. A proliferative probiotic Bifidobacterium strain in the gut ameliorates progression of metabolic disorders via microbiota modulation and acetate elevation. Scient Rep. 7(1):1–10.
   PubMedGoogle Scholar
• Björkholm B, Bok CM, Lundin A, Rafter J, Hibberd ML, Pettersson S. 2009. Intestinal microbiota regulate xenobiotic metabolism in the liver. PloS One. 4(9):e6958.
   Web of Science ®Google Scholar
• Bozward AG, Ronca V, Osei-Bordom D, Oo YH. 2021. Gut-liver immune traffic: deciphering immune-pathogenesis to underpin translational therapy. Front Immunol. 12:711217.
   PubMed Web of Science ®Google Scholar
• Chen H-Q, Gong J-Y, Xing K, Liu M-Z, Luo J-Q. 2021. Pharmacomicrobiomics: exploiting the drug-microbiota interactions in antihypertensive treatment. Front Med. 8:742394.
   Web of Science ®Google Scholar
• Claus SP, Ellero SL, Berger B, Krause L, Bruttin A, Molina J, Paris A, Want EJ, de Waziers I, Cloarec O, et al. 2011. Colonization-induced host-gut microbial metabolic interaction. MBio. 2(2):e00271-00210–e00210.
   PubMed Web of Science ®Google Scholar
• Dempsey JL, Cui JY. 2019. Microbiome is a functional modifier of P450 drug metabolism. Curr Pharmacol Rep. 5(6):481–490.
   PubMedGoogle Scholar
• Derosa L, Hellmann MD, Spaziano M, Halpenny D, Fidelle M, Rizvi H, Long N, Plodkowski AJ, Arbour KC, Chaft JE, et al. 2018. Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer. Ann Oncol. 29(6):1437–1444.
   PubMed Web of Science ®Google Scholar
• Ding M, Lang Y, Shu H, Shao J, Cui L. 2021. Microbiota–gut–brain axis and epilepsy: a review on mechanisms and potential therapeutics. Front Immunol. 12:742449.
   PubMed Web of Science ®Google Scholar
• Dingsdag SA, Hunter N. 2018. Metronidazole: an update on metabolism, structure–cytotoxicity and resistance mechanisms. J Antimicrob Chemother. 73(2):265–279.
   PubMed Web of Science ®Google Scholar
• Diot C, García-González AP, Vieira AF, Walker M, Honeywell M, Doyle H, Rivera Y, Na H, Zhang H, Lee M. 2021. Bacteria modulate tamoxifen-induced death via host fatty acid metabolism. bioRxiv.
   Google Scholar
• Gacesa R, Kurilshikov A, Vich Vila A, Sinha T, Klaassen MAY, Bolte LA, Andreu-Sánchez S, Chen L, Collij V, Hu S, et al. 2022. Environmental factors shaping the gut microbiome in a Dutch population. Nature. 604(7907):732–739.
   PubMed Web of Science ®Google Scholar
• Gomaa EZ. 2020. Human gut microbiota/microbiome in health and diseases: a review. Antonie Van Leeuwenhoek. 113(12):2019–2040.
   PubMed Web of Science ®Google Scholar
• Gong S, Lan T, Zeng L, Luo H, Yang X, Li N, Chen X, Liu Z, Li R, Win S, et al. 2018. Gut microbiota mediates diurnal variation of acetaminophen induced acute liver injury in mice. J Hepatol. 69(1):51–59.
   PubMed Web of Science ®Google Scholar
• Haiser HJ, Gootenberg DB, Chatman K, Sirasani G, Balskus EP, Turnbaugh PJ. 2013. Predicting and manipulating cardiac drug inactivation by the human gut bacterium Eggerthella lenta. Science. 341(6143):295–298.
   PubMed Web of Science ®Google Scholar
• Haiser HJ, Seim KL, Balskus EP, Turnbaugh PJ. 2014. Mechanistic insight into digoxin inactivation by Eggerthella lenta augments our understanding of its pharmacokinetics. Gut Microbes. 5(2):233–238.
   PubMed Web of Science ®Google Scholar
• Hills RD, Jr., Pontefract BA, Mishcon HR, Black CA, Sutton SC, Theberge CR. 2019. Gut Microbiome: profound implications for diet and disease. Nutrients. 11(7):1613.
   Web of Science ®Google Scholar
• Hu H, Shao W, Liu Q, Liu N, Wang Q, Xu J, Zhang X, Weng Z, Lu Q, Jiao L. 2022. Gut microbiota promotes cholesterol gallstone formation by modulating bile acid composition and biliary cholesterol secretion. Nature Commun. 13(1):1–13.
   PubMed Web of Science ®Google Scholar
• Ioannidis JPA. 2019. Reproducible pharmacokinetics. J Pharmacokinet Pharmacodyn. 46(2):111–116.
   PubMed Web of Science ®Google Scholar
• Ishii M, Toda T, Ikarashi N, Ochiai W, Sugiyama K. 2012. Effects of intestinal flora on the expression of cytochrome P450 3A in the liver. Yakugaku Zasshi. 132(3):301–310.
   PubMed Web of Science ®Google Scholar
• Karl JP, Hatch AM, Arcidiacono SM, Pearce SC, Pantoja-Feliciano IG, Doherty LA, Soares JW. 2018. Effects of psychological. Environmental and Physical Stressors on the Gut Microbiota. Front Microbiol. 9:2013.
   PubMed Web of Science ®Google Scholar
• Kim IS, Yoo D-H, Jung I-H, Lim S, Jeong J-J, Kim K-A, Bae O-N, Yoo HH, Kim D-H. 2016. Reduced metabolic activity of gut microbiota by antibiotics can potentiate the antithrombotic effect of aspirin. Biochem Pharmacol. 122:72–79.
   PubMed Web of Science ®Google Scholar
• Koppel N, Maini Rekdal V, Balskus EP. 2017. Chemical transformation of xenobiotics by the human gut microbiota. Science. 356(6344)
   PubMed Web of Science ®Google Scholar
• Lee SH, Choi N, Sung JH. 2019. Pharmacokinetic and pharmacodynamic insights from microfluidic intestine-on-a-chip models. Expert Opin Drug Metab Toxicol. 15(12):1005–1019.
   PubMed Web of Science ®Google Scholar
• Lee H, Lee S, Lee DH, Kim DW. 2021. A comparison of the gut microbiota among adult patients with drug-responsive and drug-resistant epilepsy: an exploratory study. Epilepsy Res. 172:106601.
   PubMed Web of Science ®Google Scholar
• Li H, He J, Jia W. 2016. The influence of gut microbiota on drug metabolism and toxicity. Expert Opin Drug Metab Toxicol. 12(1):31–40.
   PubMed Web of Science ®Google Scholar
• Li J, Hu FB. 2019. Research digest: reshaping the gut microbiota. Lancet Diabetes Endocrinol. 7(9):671.
   PubMed Web of Science ®Google Scholar
• Lu L, Wu Y, Zuo L, Luo X, Large PJ. 2014. Intestinal microbiome and digoxin inactivation: meal plan for digoxin users? World J Microbiol Biotechnol. 30(3):791–799.
   PubMed Web of Science ®Google Scholar
• Maini Rekdal V, Bess EN, Bisanz JE, Turnbaugh PJ, Balskus EP. 2019. Discovery and inhibition of an interspecies gut bacterial pathway for Levodopa metabolism. Science. 364(6445):eaau6323.
   PubMed Web of Science ®Google Scholar
• Malfatti MA, Kuhn EA, Murugesh DK, Mendez ME, Hum N, Thissen JB, Jaing CJ, Loots GG. 2020. Manipulation of the gut microbiome alters acetaminophen biodisposition in mice. Scientific Reports. 10(1):1–10.
   PubMed Web of Science ®Google Scholar
• Matson V, Fessler J, Bao R, Chongsuwat T, Zha Y, Alegre M-L, Luke JJ, Gajewski TF. 2018. The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients. Science. 359(6371):104–108.
   PubMed Web of Science ®Google Scholar
• Matuskova Z, Anzenbacherova E, Vecera R, Tlaskalova-Hogenova H, Kolar M, Anzenbacher P. 2014. Administration of a probiotic can change drug pharmacokinetics: effect of E. coli Nissle 1917 on amidarone absorption in rats. PloS One. 9(2):e87150.
   PubMed Web of Science ®Google Scholar
• Nakov R, Velikova T. 2020. Chemical metabolism of xenobiotics by gut microbiota. Curr Drug Metab. 21(4):260–269.
   PubMed Web of Science ®Google Scholar
• Narożańska E, Białecka M, Adamiak-Giera U, Gawrońska-Szklarz B, Sołtan W, Schinwelski M, Robowski P, Madaliński MH, Sławek J. 2014. Pharmacokinetics of levodopa in patients with Parkinson disease and motor fluctuations depending on the presence of Helicobacter pylori infection. Clin Neuropharmacol. 37(4):96–99.
   PubMed Web of Science ®Google Scholar
• Noh K, Kang YR, Nepal MR, Shakya R, Kang MJ, Kang W, Lee S, Jeong HG, Jeong TC. 2017. Impact of gut microbiota on drug metabolism: an update for safe and effective use of drugs. Arch Pharm Res. 40(12):1345–1355.
   PubMed Web of Science ®Google Scholar
• Pierantozzi M, Pietroiusti A, Brusa L, Galati S, Stefani A, Lunardi G, Fedele E, Sancesario G, Bernardi G, Bergamaschi A, et al. 2006. Helicobacter pylori eradication and l-dopa absorption in patients with PD and motor fluctuations. Neurology. 66(12):1824–1829.
   PubMed Web of Science ®Google Scholar
• Rinninella E, Raoul P, Cintoni M, Franceschi F, Miggiano GAD, Gasbarrini A, Mele MC. 2019. What is the healthy gut microbiota composition? a changing ecosystem across age, environment, diet, and diseases. Microorganisms. 7(1):14.
   PubMed Web of Science ®Google Scholar
• Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daillère R, Fluckiger A, Messaoudene M, Rauber C, Roberti MP, et al. 2018. Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors. Science. 359(6371):91–97.
   PubMed Web of Science ®Google Scholar
• Schupack DA, Mars RAT, Voelker DH, Abeykoon JP, Kashyap PC. 2022. The promise of the gut microbiome as part of individualized treatment strategies. Nat Rev Gastroenterol Hepatol. 19(1):7–25.
   PubMed Web of Science ®Google Scholar
• Selwyn FP, Cui JY, Klaassen CD. 2015. RNA-Seq quantification of hepatic drug processing genes in germ-free mice. Drug Metab Dispos. 43(10):1572–1580.
   PubMed Web of Science ®Google Scholar
• Shyangdan D, Cummins E, Royle P, Waugh N. 2011. Liraglutide for the treatment of type 2 diabetes: a single technology appraisal. Health Technol Assess. 15(1):77–86.
   PubMedGoogle Scholar
• Taniguchi C, Kawabata Y, Wada K, Yamada S, Onoue S. 2014. Microenvironmental pH-modification to improve dissolution behavior and oral absorption for drugs with pH-dependent solubility. Expert Opin Drug Deliv. 11(4):505–516.
   PubMed Web of Science ®Google Scholar
• Tilg H, Moschen AR. 2014. Microbiota and diabetes: an evolving relationship. Gut. 63(9):1513–1521.
   PubMed Web of Science ®Google Scholar
• Togao M, Kawakami K, Otsuka J, Wagai G, Ohta‐Takada Y, Kado S. 2020. Effects of gut microbiota on in vivo metabolism and tissue accumulation of cytochrome P450 3A metabolized drug: midazolam. Biopharm Drug Dispos. 41(7):275–282.
   PubMed Web of Science ®Google Scholar
• Tuteja S, Ferguson JF. 2019. Gut microbiome and response to cardiovascular drugs. Circ Genom Precis Med. 12(9):e002314.
   PubMed Web of Science ®Google Scholar
• Wallace BD, Wang H, Lane KT, Scott JE, Orans J, Koo JS, Venkatesh M, Jobin C, Yeh L-A, Mani S, et al. 2010. Alleviating cancer drug toxicity by inhibiting a bacterial enzyme. Science. 330(6005):831–835.
   PubMed Web of Science ®Google Scholar
• Wang Y, Sun L, Chen S, Guo S, Yue T, Hou Q, Feng M, Xu H, Liu Y, Wang P. 2019. The administration of Escherichia coli Nissle 1917 ameliorates irinotecan–induced intestinal barrier dysfunction and gut microbial dysbiosis in mice. Life Sciences. 231:116529.
   PubMed Web of Science ®Google Scholar
• Weersma RK, Zhernakova A, Fu J. 2020. Interaction between drugs and the gut microbiome. Gut. 69(8):1510–1519.
   PubMed Web of Science ®Google Scholar
• Whang A, Nagpal R, Yadav H. 2019. Bi-directional drug-microbiome interactions of anti-diabetics. EBioMedicine. 39:591–602.
   PubMed Web of Science ®Google Scholar
• Wilson ID, Nicholson JK. 2017. Gut microbiome interactions with drug metabolism, efficacy, and toxicity. Transl Res. 179:204–222.
   PubMed Web of Science ®Google Scholar
• Winston JA, Theriot CM. 2020. Diversification of host bile acids by members of the gut microbiota. Gut Microbes. 11(2):158–171.
   PubMed Web of Science ®Google Scholar
• Xie Y, Hu F, Xiang D, Lu H, Li W, Zhao A, Huang L, Wang R. 2020. The metabolic effect of gut microbiota on drugs. Drug Metab Rev. 52(1):139–156.
   PubMed Web of Science ®Google Scholar
• Yang L, Yuan TJ, Wan Y, Li WW, Liu C, Jiang S, Duan JA. 2022. Quorum sensing: a new perspective to reveal the interaction between gut microbiota and host. Future Microbiol. 17:293–309.
   PubMed Web of Science ®Google Scholar
• Yoo D-H, Kim IS, Van Le TK, Jung I-H, Yoo HH, Kim D-H. 2014. Gut microbiota-mediated drug interactions between lovastatin and antibiotics. Drug Metab Dispos. 42(9):1508–1513.
   PubMed Web of Science ®Google Scholar
• Yoo HH, Kim IS, Yoo D-H, Kim D-H. 2016. Effects of orally administered antibiotics on the bioavailability of amlodipine: gut microbiota-mediated drug interaction. J Hypertens. 34(1):156–162.
   PubMed Web of Science ®Google Scholar
• Zemanová N, Lněničková K, Vavrečková M, Anzenbacherová E, Anzenbacher P, Zapletalová I, Hermanová P, Hudcovic T, Kozáková H, Jourová L. 2021. Gut microbiome affects the metabolism of metronidazole in mice through regulation of hepatic cytochromes P450 expression. PloS One. 16(11):e0259643.
   PubMed Web of Science ®Google Scholar
• Zhang X, Han Y, Huang W, Jin M, Gao Z. 2021. The influence of the gut microbiota on the bioavailability of oral drugs. Acta Pharm Sin B. 11(7):1789–1812.
   PubMed Web of Science ®Google Scholar
• Zhang J, Sun Y, Wang R, Zhang J. 2019. Gut microbiota-mediated drug-drug interaction between amoxicillin and aspirin. Scient Rep. 9(1):1–8.
   PubMed Web of Science ®Google Scholar
• Zhang J, Zhang J, Wang R. 2018. Gut microbiota modulates drug pharmacokinetics. Drug Metab Rev. 50(3):357–368.
   PubMed Web of Science ®Google Scholar
• Zhao L, Chen Y, Xia F, Abudukerimu B, Zhang W, Guo Y, Wang N, Lu Y. 2018. A glucagon-like peptide-1 receptor agonist lowers weight by modulating the structure of gut microbiota. Front Endocrinol. 9:233.
   PubMed Web of Science ®Google Scholar
• Zimmermann M, Zimmermann-Kogadeeva M, Wegmann R, Goodman AL. 2019. Separating host and microbiome contributions to drug pharmacokinetics and toxicity. Science. 363(6427):eaat9931.
   Web of Science ®Google Scholar
• Zimmermann-Kogadeeva M, Zimmermann M, Goodman AL. 2020. Insights from pharmacokinetic models of host-microbiome drug metabolism. Gut Microbes. 11(3):587–596.
   PubMed Web of Science ®Google Scholar